• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?CheckMate-915研究：辅助性抗细胞毒性T淋巴细胞相关抗原4（CTLA-4）阻断疗法在切除的黑色素瘤中起作用吗？
Ann Transl Med. 2023 Aug 30;11(10):370. doi: 10.21037/atm-23-754. Epub 2023 Mar 6.
2
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.辅助纳武利尤单抗对比伊匹单抗用于可切除 IIIB-C 期和 IV 期黑色素瘤（CheckMate 238 研究）：一项多中心、双盲、随机、对照、III 期临床试验的 4 年结果。
Lancet Oncol. 2020 Nov;21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0. Epub 2020 Sep 19.
3
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.CheckMate 238 研究的 III/IV 期黑色素瘤完全切除术后纳武利尤单抗与伊匹单抗辅助治疗的日本亚组分析。
J Dermatol. 2019 Dec;46(12):1197-1201. doi: 10.1111/1346-8138.15103. Epub 2019 Oct 22.
4
Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.基于汇总临床试验数据的纳武利尤单抗对比观察或伊匹单抗作为辅助治疗在可切除黑色素瘤中的间接治疗比较。
Adv Ther. 2019 Oct;36(10):2783-2796. doi: 10.1007/s12325-019-01060-y. Epub 2019 Aug 22.
5
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.基线血清自身抗体特征可预测接受辅助免疫检查点阻断治疗的黑色素瘤患者的复发和毒性。
Clin Cancer Res. 2022 Sep 15;28(18):4121-4130. doi: 10.1158/1078-0432.CCR-22-0404.
6
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.辅助纳武利尤单抗对比伊匹木单抗用于 III 期/IV 期黑色素瘤切除术后：CheckMate 238 的 5 年疗效和生物标志物结果。
Clin Cancer Res. 2023 Sep 1;29(17):3352-3361. doi: 10.1158/1078-0432.CCR-22-3145.
7
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer; Nivolumab and Ipilimumab in Advanced Melanoma; Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma; Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma; Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma; Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy; Genetic Basis for Clinical Response to CTLA-4 Blockade; Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma; Nivolumab plus Ipilimumab in Advanced Melanoma; Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma; Hepatotoxicity with Combination of Vemurafenib and Ipilimumab.可切除肺癌的新辅助PD-1阻断；晚期黑色素瘤中的纳武单抗和伊匹单抗；晚期黑色素瘤联合使用纳武单抗和伊匹单抗的总生存期；伊匹单抗辅助治疗Ⅲ期黑色素瘤的生存期延长；未经治疗的黑色素瘤中联合使用纳武单抗和伊匹单抗或单药治疗；未经治疗的黑色素瘤中联合使用纳武单抗和伊匹单抗或单药治疗；未经治疗的黑色素瘤中纳武单抗和伊匹单抗与伊匹单抗对比；一剂免疫疗法快速根除巨大黑色素瘤肿块；CTLA-4阻断临床反应的遗传基础；黑色素瘤中CTLA-4阻断临床反应的遗传基础；晚期黑色素瘤中的纳武单抗加伊匹单抗；黑色素瘤中帕博利珠单抗（抗PD-1）的安全性和肿瘤反应；维莫非尼和伊匹单抗联合使用的肝毒性。
N Engl J Med. 2018 Nov 29;379(22):2185. doi: 10.1056/NEJMx180040. Epub 2018 Nov 9.
8
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).纳武利尤单抗联合伊匹木单抗辅助治疗与纳武利尤单抗单药治疗 IIIB-D 期或 IV 期黑色素瘤患者的比较（CheckMate 915）
J Clin Oncol. 2023 Jan 20;41(3):517-527. doi: 10.1200/JCO.22.00533. Epub 2022 Sep 26.
9
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.辅助纳武利尤单抗对比伊匹单抗（CheckMate 238 试验）：根据 AJCC-8 分期标准重新评估 III 期黑色素瘤患者的 4 年疗效结局。
Eur J Cancer. 2022 Sep;173:285-296. doi: 10.1016/j.ejca.2022.06.041. Epub 2022 Aug 11.
10
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.纳武利尤单抗对比安慰剂作为 III 期黑色素瘤切除术后辅助治疗：复发无进展生存和总生存的倾向评分加权间接治疗比较和需要治疗的人数分析。
Cancer Immunol Immunother. 2023 Apr;72(4):945-954. doi: 10.1007/s00262-022-03302-5. Epub 2022 Oct 5.

引用本文的文献

1
Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.教育评论：免疫检查点阻断在黑色素瘤治疗中的临床应用。
Ann Surg Oncol. 2024 Mar;31(3):1865-1879. doi: 10.1245/s10434-023-14587-w. Epub 2023 Nov 21.

本文引用的文献

1
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.辅助纳武利尤单抗联合伊匹单抗用于高风险切除黑色素瘤的 II 期临床和免疫相关研究。
J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005684.
2
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).纳武利尤单抗联合伊匹木单抗辅助治疗与纳武利尤单抗单药治疗 IIIB-D 期或 IV 期黑色素瘤患者的比较（CheckMate 915）
J Clin Oncol. 2023 Jan 20;41(3):517-527. doi: 10.1200/JCO.22.00533. Epub 2022 Sep 26.
3
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.纳武利尤单抗联合伊匹单抗或纳武利尤单抗单药用于无疾病证据的 IV 期黑色素瘤患者的辅助治疗（IMMUNED）：一项随机、双盲、II 期试验的最终结果。
Lancet. 2022 Oct 1;400(10358):1117-1129. doi: 10.1016/S0140-6736(22)01654-3. Epub 2022 Sep 10.
4
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.纳武利尤单抗联合或不联合伊匹单抗化疗放疗治疗肌层浸润性膀胱癌的 1 期研究。
Eur Urol. 2022 Nov;82(5):518-526. doi: 10.1016/j.eururo.2022.07.009. Epub 2022 Aug 3.
5
Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.新辅助伊匹单抗和纳武利尤单抗治疗高危 III 期黑色素瘤后的个体化反应导向手术和辅助治疗：PRADO 试验。
Nat Med. 2022 Jun;28(6):1178-1188. doi: 10.1038/s41591-022-01851-x. Epub 2022 Jun 5.
6
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.Relatlimab 和 Nivolumab 对比 Nivolumab 用于未经治疗的晚期黑色素瘤。
N Engl J Med. 2022 Jan 6;386(1):24-34. doi: 10.1056/NEJMoa2109970.
7
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).基于早期、中期影像学评估的晚期黑色素瘤患者纳武利尤单抗+伊匹单抗免疫治疗的适应性剂量调整（ADAPT-IT 研究）。
J Clin Oncol. 2022 Apr 1;40(10):1059-1067. doi: 10.1200/JCO.21.01570. Epub 2021 Dec 20.
8
CheckMate-067: Raising the Bar for the Next Decade in Oncology.CheckMate-067研究：为肿瘤学领域未来十年树立更高标准
J Clin Oncol. 2022 Jan 10;40(2):111-113. doi: 10.1200/JCO.21.02549. Epub 2021 Dec 2.
9
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.纳武利尤单抗联合伊匹单抗或纳武利尤单抗对比伊匹单抗治疗晚期黑色素瘤患者的长期结局。
J Clin Oncol. 2022 Jan 10;40(2):127-137. doi: 10.1200/JCO.21.02229. Epub 2021 Nov 24.
10
Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.辅助用伊匹单抗（3 或 10 mg/kg）对比高剂量干扰素 α-2b 用于切除的高风险黑色素瘤的 III 期研究：北美协作组 E1609。
J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27.

CheckMate-915: does adjuvant CTLA-4 blockade play a role in resected melanoma?

作者信息

Su David, Kluger Harriet, Weiss Sarah A

机构信息

Section of Surgical Oncology, Yale University School of Medicine, New Haven, CT, USA.

Division of Medical Oncology, Yale University School of Medicine, New Haven, CT, USA.

出版信息

Ann Transl Med. 2023 Aug 30;11(10):370. doi: 10.21037/atm-23-754. Epub 2023 Mar 6.

DOI:10.21037/atm-23-754
PMID:37675335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10477634/
Abstract
摘要